These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Ribosomal Protein Mutations Result in Constitutive p53 Protein Degradation through Impairment of the AKT Pathway. Antunes AT; Goos YJ; Pereboom TC; Hermkens D; Wlodarski MW; Da Costa L; MacInnes AW PLoS Genet; 2015 Jul; 11(7):e1005326. PubMed ID: 26132763 [TBL] [Abstract][Full Text] [Related]
5. Targeting the ubiquitin-proteasome system to activate wild-type p53 for cancer therapy. Allende-Vega N; Saville MK Semin Cancer Biol; 2010 Feb; 20(1):29-39. PubMed ID: 19897040 [TBL] [Abstract][Full Text] [Related]
6. A mechanism of ubiquitin-independent proteasomal degradation of the tumor suppressors p53 and p73. Asher G; Tsvetkov P; Kahana C; Shaul Y Genes Dev; 2005 Feb; 19(3):316-21. PubMed ID: 15687255 [TBL] [Abstract][Full Text] [Related]
9. Oligomerization conditions Mdm2-mediated efficient p53 polyubiquitylation but not its proteasomal degradation. Hjerpe R; Aillet F; Lopitz-Otsoa F; Lang V; Torres-Ramos M; Farrás R; Hay RT; Rodríguez MS Int J Biochem Cell Biol; 2010 May; 42(5):725-35. PubMed ID: 20080206 [TBL] [Abstract][Full Text] [Related]
10. Dissecting the pathways that destabilize mutant p53: the proteasome or autophagy? Choudhury S; Kolukula VK; Preet A; Albanese C; Avantaggiati ML Cell Cycle; 2013 Apr; 12(7):1022-9. PubMed ID: 23466706 [TBL] [Abstract][Full Text] [Related]
11. Mdm2 facilitates the association of p53 with the proteasome. Kulikov R; Letienne J; Kaur M; Grossman SR; Arts J; Blattner C Proc Natl Acad Sci U S A; 2010 Jun; 107(22):10038-43. PubMed ID: 20479273 [TBL] [Abstract][Full Text] [Related]
12. The chaperone-associated ubiquitin ligase CHIP is able to target p53 for proteasomal degradation. Esser C; Scheffner M; Höhfeld J J Biol Chem; 2005 Jul; 280(29):27443-8. PubMed ID: 15911628 [TBL] [Abstract][Full Text] [Related]
13. Mdm-2 and ubiquitin-independent p53 proteasomal degradation regulated by NQO1. Asher G; Lotem J; Sachs L; Kahana C; Shaul Y Proc Natl Acad Sci U S A; 2002 Oct; 99(20):13125-30. PubMed ID: 12232053 [TBL] [Abstract][Full Text] [Related]
15. NRF3-POMP-20S Proteasome Assembly Axis Promotes Cancer Development via Ubiquitin-Independent Proteolysis of p53 and Retinoblastoma Protein. Waku T; Nakamura N; Koji M; Watanabe H; Katoh H; Tatsumi C; Tamura N; Hatanaka A; Hirose S; Katayama H; Tani M; Kubo Y; Hamazaki J; Hamakubo T; Watanabe A; Murata S; Kobayashi A Mol Cell Biol; 2020 Apr; 40(10):. PubMed ID: 32123008 [TBL] [Abstract][Full Text] [Related]
16. Modulation of p53 degradation via MDM2-mediated ubiquitylation and the ubiquitin-proteasome system during reperfusion after stroke: role of oxidative stress. Saito A; Hayashi T; Okuno S; Nishi T; Chan PH J Cereb Blood Flow Metab; 2005 Feb; 25(2):267-80. PubMed ID: 15678128 [TBL] [Abstract][Full Text] [Related]
17. Gambogic acid-induced degradation of mutant p53 is mediated by proteasome and related to CHIP. Wang J; Zhao Q; Qi Q; Gu HY; Rong JJ; Mu R; Zou MJ; Tao L; You QD; Guo QL J Cell Biochem; 2011 Feb; 112(2):509-19. PubMed ID: 21268072 [TBL] [Abstract][Full Text] [Related]
18. Prostate carcinoma cell death resulting from inhibition of proteasome activity is independent of functional Bcl-2 and p53. Herrmann JL; Briones F; Brisbay S; Logothetis CJ; McDonnell TJ Oncogene; 1998 Dec; 17(22):2889-99. PubMed ID: 9879995 [TBL] [Abstract][Full Text] [Related]
19. p53 proteasomal degradation: poly-ubiquitination is not the whole story. Asher G; Shaul Y Cell Cycle; 2005 Aug; 4(8):1015-8. PubMed ID: 16082197 [TBL] [Abstract][Full Text] [Related]
20. The oncoprotein gankyrin negatively regulates both p53 and RB by enhancing proteasomal degradation. Higashitsuji H; Liu Y; Mayer RJ; Fujita J Cell Cycle; 2005 Oct; 4(10):1335-7. PubMed ID: 16177571 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]